Cara Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview

Tvardi Therapeutics

04/11/2022 17:09

* Cara Therapeutics Inc  CARA.OQ   CARA.O  is expected
to show a
fall in quarterly revenue when it reports  results on November
7. 
    * The Stamford Connecticut-based  company is expected to
report  a
51.5% decrease in revenue to $9.831 million from $20.27 million
a year ago, according to the mean estimate from 6 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Cara Therapeutics
Inc is
for a loss of 42 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cara
Therapeutics
Inc is $27​, above​ its last closing price of $9.19. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.25       -0.25      -0.08     Beat    68.4
 Mar. 31 2022  -0.54       -0.54      -0.52     Beat    3.1
 Dec. 31 2021  -0.50       -0.52      -0.63     Missed  -22.2​
 Sep. 30 2021  -0.35       -0.40      -0.02     Beat    94.9
 ​​Jun.        -0.50       -0.53      -0.61     Missed  -14.5
 30 2021                                                
 Mar. 31 2021  -0.65       -0.59      -0.47     Beat    20.3​
 Dec. 31 2020  0.37        0.36       1.59      Beat    336.5
 Sep. 30 2020  -0.61       -0.60      -0.35     Beat    41.4
 This summary was machine generated November 4 at 17:07 GMT.  All
figures in US dollars  unless otherwise stated